Interestingly, as shown in (Fig. 7a–f), while DYRK1A inhibition or topotecan treatment alone reduced both tumor volume and tumor weight, these effects were greatly enhanced in animals transplanted with DYRK1A-KO cells and further treated with the chemotherapy drug topotecan in both colon and TNBC preclinical in vivo models. Here, DYRK1A is linked to neoplasm.